The PRESupply project aims to make accessible state-of-the-art optimization solutions in Supply Chain Management to SME’s. It will help them generating a maximum of value from optimized decisions towards their different supply chain challenges. PRESupply project will focus on production, inventory, logistic and demand management issues. The PRESupply project will develop a flexible and modular platform, using integrated, predictive […]read more
Clinical trial supply overage – How to reduce product wastage while keeping a perfect service level for patients?
For decades, risk in clinical trial supply has been mitigated by maintaining buffers of drug available throughout the supply chain. Buffers are necessary to cover the inherent variability in the demand of clinical trials. When not consumed by patients during the trial, these buffers result in unused drug, or “overage”. When investigational medicines are readily available and not expensive, having higher overage in a study can be accepted by the company in order to ensure no risk to patient service level.read more
N-SIDE is pleased to announce the launch of CT-PRO, a new solution providing risk-based optimization for drug substance (i.e. API) and drug product production forecast and planning. CT-PRO is a cutting-edge tool based on optimization algorithms that aims to manage the forecast at the drug substance and drug product level, pooling the need of multiple […]read more
Pharmaceutical organizations are putting more and more pressure on clinical supply chain managers to minimize study overage. Study overage represents the kits that will expire unused at the investigational sites, local depots and central depot. Some overage is absolutely needed, both as insurance against the unexpected events that can occur during the trial and as a result of the design of the protocol and distribution network.
But often the question is raised (and not only by higher management): is the requested amount of overage absolutely necessary or is it possible to decrease it?